Cantor Fitzgerald Comments on MiMedx Group FY2025 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for MiMedx Group in a note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of $0.31 per share for the year, down from their previous estimate of $0.33. Cantor Fitzgerald currently has a "Overweight" rating and a $13.00 target price on the stock. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%.

Separately, StockNews.com lowered shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $12.00.

Remove Ads

MiMedx Group Stock Performance

Shares of MiMedx Group stock traded down $0.09 on Monday, reaching $8.00. 527,445 shares of the stock were exchanged, compared to its average volume of 711,695. The business has a 50 day moving average price of $8.63 and a two-hundred day moving average price of $7.75. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of 14.55 and a beta of 1.97. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

Institutional Trading of MiMedx Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC boosted its position in MiMedx Group by 133.6% in the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock worth $1,806,000 after purchasing an additional 174,797 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock valued at $1,757,000 after purchasing an additional 215,995 shares during the period. Barclays PLC boosted its holdings in MiMedx Group by 163.9% during the third quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after buying an additional 163,005 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in MiMedx Group by 88.6% during the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company's stock worth $145,000 after buying an additional 11,557 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its position in MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock valued at $6,074,000 after buying an additional 770,744 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.